CSBR Champions Oncology, Inc. - Common Stock
$5,07
Kurs · Aug 19, 2026
Fundamentaldaten per Jul 27, 2026
52W-Spanne
$5–$8
6% of range
Analystenbewertung
BUY
7 analysts
Kursziel
—
P/E (TTM)
-63.4
ROE
-30.5%
Nettogewinnmarge
-2.0%
Über Champions Oncology, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Mehr lesen
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
TumorGrafts
Champions TumorGrafts maintain the microenvironment surrounding the tumor and have been shown to have high correlation to the patient’s tumor. Due to this close resemblance to the human tumor, TumorGrafts are highly predictive of treatment outcomes in patients. Studies have shown the mouse avatars predict clinical benefit in 80% of patients. Approximately 450 TumorGrafts have been established as of April 2014.
TumorGrafts are also being used as a pre-clinical research tool to improve clinical drug development. Compared to traditional xenograft models, TumorGrafts, have a greater degree of accuracy in predicting clinical effectiveness of oncology drugs and thus can decrease clinical risk for drug developers. Champions has formed partnerships with multiple drug developers, including Teva and Pfizer.
The process
When a cancer patient undergoes surgery or biopsy, a living sample of the tumor is obtained and implanted into the mouse, creating a mouse avatar. Once the TumorGraft has successfully grown, the tumor is then propagated in a second generation of mice and tested against a panel of cancer drugs and drug combinations to help identify more accurately which treatment regimen is likely to be most effective in a specific patient. In this way, various drugs are tested on a live sample of the actual patient's tumor, rather than on the patient. This reduces the likelihood of treatment with ineffective drugs and their associated side effects, and it increases the likelihood of finding a treatment that will work against the patient's tumor. For patients whose tumors have also undergone molecular testing, such as next-generation sequencing, the selection of potential drugs is further guided by any and all applicable results. In the event the cancer progresses or recurs, Champions also banks, or stores, each successful TumorGraft for potential future patient use.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
CSBR Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$5.07
Marktkapitalisierung
$70M
P/E (TTM)
-63.4
EPS (TTM)
$-0.08
Umsatz (TTM)
$59M
Dividendenrendite
—
ROE
-30.5%
Verschuldungsgrad
—
52W-Spanne
$5 – $8
CSBR Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$59M
2018-04-30
→
2026-04-30
EPS
$-0.08
2018-04-30
→
2026-04-30
Freier Cashflow
$-5M
2017-04-30
→
2026-04-30
Margen
-2.0%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
CSBR
Peer-Median
P/E (TTM)
-63.4
31.9
P/S (TTM) (K/V (TTM))
1.2
2.5
P/B (K/B)
17.9
2.2
Price / FCF (Kurs / FCF)
-14.0
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
CSBR
Peer-Median
Operating Margin (Betriebsgewinnmarge)
-1.9%
—
Net Profit Margin (Nettogewinnmarge)
-2.0%
-71.9%
ROA
-4.0%
-23.6%
ROE
-30.5%
-35.1%
ROIC
-36.6%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
CSBR
Peer-Median
Current Ratio (Liquiditätsgrad)
1.0
4.5
Quick Ratio
0.9
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
CSBR
Peer-Median
Revenue YoY (Umsatz YoY)
4.4%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
3.3%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
7.7%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
CSBR
Peer-Median
CSBR Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
7 Analysten
- Starker Kauf 2 28,6%
- Kauf 4 57,1%
- Halten 1 14,3%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.01%
Nächster Bericht
Sep 16, 2026
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $-0.05 | $-0.05 | 0.00% |
| 31. März 2026 | $-0.02 | $0.09 | -0.11% |
| 31. Dezember 2025 | $0.02 | $0.01 | 0.01% |
| 30. September 2025 | $0.02 | $-0.01 | 0.03% |
| 30. Juni 2025 | $-0.07 | $-0.20 | 0.13% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| CSBR | $83M | -74.5 | 4.4% | -2.0% | -30.5% | — |
| MXCT | $166M | -3.7 | -14.5% | -135.1% | -24.6% | 81.2% |
| QTRX | $297M | -2.5 | 1.1% | -77.1% | -36.4% | 46.8% |
| NAUT | $247M | -4.1 | — | — | -34.9% | — |
| SEER | — | -1.4 | 17.0% | — | — | — |
| RPID | — | -2.8 | 19.7% | -140.3% | -107.4% | — |
| HYFT | — | — | — | — | — | — |
| HBIO | $30M | -0.5 | -8.1% | -65.5% | -384.8% | 57.7% |
| TMO | $257.86B | 32.7 | 3.9% | 15.0% | 13.0% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 15
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59M | $57M | $50M | $54M | $49M | $41M | $32M | $3M | $20M | |
| Cost of Revenue | $31M | $28M | $29M | $30M | $24M | $21M | $17M | · | · | |
| R&D Expense | $9M | $7M | $10M | $12M | $9M | $7M | $6M | $5M | $4M | |
| SG&A Expense | $11M | $9M | $11M | $10M | $9M | $7M | $7M | $5M | $4M | |
| Operating Expenses | · | · | · | · | · | · | $34M | $27M | $22M | |
| Operating Income | $-1M | $5M | $-7M | $-5M | $607.0K | $366.0K | $-2M | $270.0K | $-1M | |
| Other Non-op | $211.0K | $73.0K | $48.0K | $-11.0K | $-24.0K | $71.0K | $-42.0K | $-39.0K | $-89.0K | |
| Pretax Income | $-929.0K | $5M | $-7M | $-5M | $583.0K | $437.0K | $-2M | $231.0K | $-1M | |
| Income Tax | $246.0K | $-75.0K | $-32.0K | $68.0K | $35.0K | $75.0K | $130.0K | $103.0K | $33.0K | |
| Net Income | $-1M | $5M | $-7M | $-5M | $548.0K | $362.0K | $-2M | $128.0K | $-1M | |
| EPS (Basic) | $-0.08 | $0.34 | $-0.54 | $-0.39 | $0.04 | $0.03 | $-0.18 | $0.01 | $-0.13 | |
| EPS (Diluted) | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 | $0.02 | $-0.18 | $0.01 | $-0.13 | |
| Shares (Basic) | 13,832,385 | 13,659,786 | 13,547,604 | 13,541,559 | 13,197,170 | 13,138,995 | 11,843,463 | 11,340,184 | 10,991,105 | |
| Shares (Diluted) | 13,832,385 | 14,266,781 | 13,547,604 | 13,541,559 | 14,159,799 | 14,573,561 | 11,843,463 | 14,096,117 | 10,991,105 | |
| EBITDA | $260.0K | $6M | $-6M | $-3M | $2M | $2M | $-978.0K | $876.0K | $-994.0K |
Bilanz 22
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5M | $10M | $3M | $10M | $9M | $5M | $8M | $3M | $856.0K | |
| Receivables | $13M | $11M | $10M | $8M | $10M | $7M | $5M | $4M | $4M | |
| Prepaid Expense | $1M | $1M | $1M | $1M | $1M | $957.0K | $385.0K | $308.0K | $287.0K | |
| Current Assets | $19M | $22M | $14M | $19M | $20M | $13M | $13M | $8M | $5M | |
| PP&E (Net) | · | · | · | · | $7M | $6M | $4M | $3M | $2M | |
| PP&E (Gross) | $16M | $16M | $16M | $16M | $13M | $10M | $7M | $5M | $4M | |
| Accum. Depreciation | $13M | $12M | $10M | $9M | $6M | $4M | $3M | $2M | $1M | |
| Goodwill | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $670.0K | $669.0K | |
| Other Non-current Assets | $212.0K | $196.0K | $185.0K | $15.0K | $15.0K | $15.0K | $128.0K | $128.0K | $116.0K | |
| Total Assets | $27M | $32M | $26M | $34M | $35M | $28M | $21M | $11M | $8M | |
| Accounts Payable | $7M | $4M | $6M | $5M | $3M | $2M | $3M | $3M | $2M | |
| Accrued Liabilities | $3M | $3M | $2M | $2M | $2M | $2M | $3M | $1M | $569.0K | |
| Current Liabilities | $20M | $24M | $22M | $22M | $17M | $11M | $12M | $8M | $7M | |
| Capital Leases | $3M | $5M | $6M | $7M | $8M | $9M | $3M | $0 | $17.0K | |
| Other Non-current Liabilities | $7.0K | $85.0K | $401.0K | $551.0K | $391.0K | $181.0K | $178.0K | $151.0K | $151.0K | |
| Total Liabilities | $23M | $29M | $28M | $30M | $26M | $20M | $16M | $9M | $8M | |
| Common Stock | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $13.0K | $13.0K | $12.0K | $11.0K | |
| Retained Earnings | $-81M | $-80M | $-85M | $-77M | $-72M | $-73M | $-73M | $-71M | $-71M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $74.0K | $0 | · | · | $0 | $1M | |
| Stockholders' Equity | $4M | $4M | $-2M | $5M | $9M | $7M | $5M | $2M | $3.0K | |
| Liabilities + Equity | $27M | $32M | $26M | $34M | $35M | $28M | $21M | $11M | $8M | |
| Shares Outstanding | 13,886,826 | 13,777,170 | 13,714,099 | 13,558,650 | 13,522,441 | 13,414,066 | 12,726,728 | 11,619,538 | 11,003,228 |
Cashflow 14
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $2M | $2M | $2M | $2M | $925.0K | $825.0K | $606.0K | $360.0K | |
| Stock-based Comp | $1M | $654.0K | $1M | $864.0K | $912.0K | $598.0K | $600.0K | $636.0K | $1M | |
| Deferred Tax | $0 | $0 | · | · | · | · | · | · | · | |
| Other Non-cash | $-6M | $431.0K | $-2M | $6M | $4M | $-4M | $3M | $492.0K | $-1M | |
| Operating Cash Flow | $-4M | $7M | $-6M | $4M | $6M | $-2M | $3M | $2M | $-1M | |
| CapEx | $564.0K | $389.0K | $836.0K | $3M | $2M | $3M | $2M | $834.0K | $1M | |
| Investing Cash Flow | $-540.0K | $-389.0K | $-836.0K | $-3M | $-2M | $-3M | $-2M | $-834.0K | $-1M | |
| Stock Issued | · | · | · | · | · | · | · | · | $0 | |
| Stock Repurchased | · | $0 | $634.0K | $74.0K | $0 | · | · | · | · | |
| Net Stock Activity | · | $0 | $-634.0K | $-74.0K | · | · | · | · | $0 | |
| Financing Cash Flow | $99.0K | $170.0K | $-527.0K | $11.0K | $207.0K | $1M | $4M | $1M | $13.0K | |
| Net Change in Cash | $-5M | $7M | $-8M | $1M | $4M | $-4M | $5M | $2M | $-2M | |
| Taxes Paid | $242.0K | $43.0K | · | · | · | · | · | · | · | |
| Free Cash Flow | $-5M | $7M | $-7M | $1M | $4M | $-5M | $685.0K | $1M | $-2M |
Rentabilität 7
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1.9% | 8.0% | -14.7% | -9.8% | 1.2% | 0.89% | · | 1.0% | · | |
| Net Margin | -2.0% | 8.3% | -14.5% | -9.9% | 1.1% | 0.88% | · | 0.47% | · | |
| Pretax Margin | -1.6% | 8.1% | -14.6% | -9.8% | 1.2% | 1.1% | · | 0.85% | · | |
| EBITDA Margin | 0.44% | 10.8% | -11.3% | -5.9% | 4.3% | 3.8% | · | 3.2% | · | |
| ROA | -4.0% | 16.1% | -24.1% | -15.3% | 1.7% | 1.5% | -12.5% | 1.3% | -18.6% | |
| ROE | -30.5% | 211.1% | 367.4% | -91.2% | 6.0% | 4.7% | -36.9% | 5.6% | -744.4% | |
| ROIC | -36.6% | 122.7% | 384.9% | -114.8% | 6.3% | 4.1% | -36.3% | 6.7% | -46165.5% |
Liquidität & Solvenz 2
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.9 | 0.6 | 0.9 | 1.1 | 1.1 | 1.1 | 1.0 | 0.7 | |
| Quick Ratio | 0.9 | 0.9 | 0.6 | 0.8 | 1.1 | 1.0 | 1.1 | 0.9 | 0.6 |
Effizienz 2
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 2.0 | 1.9 | 1.7 | 1.5 | 1.6 | 1.7 | · | 2.8 | · | |
| Receivables Turnover | 4.9 | 5.5 | 5.8 | 6.3 | 6.0 | 7.0 | · | 6.5 | · |
Wachstumsraten 7
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 4.4% | 13.5% | -6.9% | 9.7% | 19.7% | 27.8% | · | · | · | |
| Revenue CAGR 3Y | 3.3% | 5.1% | 6.9% | 18.8% | · | · | · | · | · | |
| Revenue CAGR 5Y | 7.7% | 12.1% | · | · | · | · | · | · | · | |
| EPS YoY | · | · | · | · | 100.0% | · | · | · | · | |
| EPS CAGR 3Y | · | 102.1% | · | · | · | · | · | · | · | |
| Net Income YoY | · | · | · | · | 51.4% | · | · | · | · | |
| Net Income CAGR 3Y | · | 104.7% | · | · | · | · | · | · | · |
Bewertung (TTM) 10
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $59M | $57M | $50M | $54M | $49M | $41M | $32M | $3M | $20M | |
| Net Income TTM | $-1M | $5M | $-7M | $-5M | $548.0K | $362.0K | $-2M | $128.0K | $-1M | |
| Market Cap | $83M | $99M | $66M | $67M | $104M | $144M | $98M | $106M | $48M | |
| P/E | -74.5 | 21.7 | -9.0 | -12.6 | 192.0 | 536.5 | -42.9 | 908.0 | -33.4 | |
| P/S | 1.4 | 1.7 | 1.3 | 1.2 | 2.1 | 3.5 | 3.1 | 36.4 | 2.4 | |
| P/B | 21.0 | 26.1 | -34.6 | 14.4 | 11.4 | 19.4 | 18.5 | 47.1 | 15918.0 | |
| P / Tangible Book | 23.0 | 28.7 | · | 15.5 | 11.9 | 20.3 | 20.6 | · | · | |
| P / Cash Flow | -18.5 | 13.3 | -10.7 | 16.8 | 16.0 | -85.6 | 33.8 | 56.7 | -39.0 | |
| P / FCF | -16.4 | 14.1 | -9.4 | 60.6 | 25.2 | -29.0 | 143.4 | 102.6 | -19.5 | |
| Earnings Yield | -1.3% | 4.6% | -11.1% | -7.9% | 0.52% | 0.19% | -2.3% | 0.11% | -3.0% |
Gewinn- und Verlustrechnung 14
| Kennzahl | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $17M | $15M | $14M | $12M | $17M | $13M | $14M | $14M | $12M | $12M | $13M | $13M | $13M | $14M | $14M | |
| Cost of Revenue | $7M | $9M | $7M | $8M | $7M | $7M | $7M | $7M | $7M | $8M | $7M | $8M | $7M | $8M | $7M | $7M | |
| R&D Expense | $2M | $2M | $3M | $2M | $2M | $2M | $2M | $1M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | |
| SG&A Expense | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $2M | |
| Operating Income | $-522.0K | $-276.0K | $185.0K | $-527.0K | $-2M | $4M | $732.0K | $1M | $-272.0K | $-3M | $-2M | $-3M | $-3M | $-2M | $7.0K | $-284.0K | |
| Other Non-op | $27.0K | $39.0K | $70.0K | $75.0K | $42.0K | $19.0K | $7.0K | $5.0K | $81.0K | $58.0K | $-105.0K | $14.0K | $-20.0K | $36.0K | $-9.0K | $-18.0K | |
| Pretax Income | $-495.0K | $-237.0K | $255.0K | $-452.0K | $-2M | $5M | $739.0K | $1M | $-191.0K | $-3M | $-2M | $-3M | $-3M | $-2M | $-2.0K | $-302.0K | |
| Income Tax | $172.0K | $42.0K | $18.0K | $14.0K | $-130.0K | $23.0K | $11.0K | $21.0K | $-82.0K | $11.0K | $11.0K | $28.0K | $20.0K | $17.0K | $14.0K | $17.0K | |
| Net Income | $-728.0K | $-279.0K | $268.0K | $-436.0K | $-2M | $4M | $728.0K | $1M | $-109.0K | $-3M | $-2M | $-3M | $-3M | $-2M | $-16.0K | $-319.0K | |
| EPS (Basic) | $-0.05 | $-0.02 | $0.02 | $-0.03 | $-0.14 | $0.33 | $0.05 | $0.10 | $-0.01 | $-0.19 | $-0.15 | $-0.19 | $-0.19 | $-0.18 | $0.00 | $-0.02 | |
| EPS (Diluted) | $-0.05 | $-0.02 | $0.02 | $-0.03 | $-0.12 | $0.31 | $0.05 | $0.09 | $-0.01 | $-0.19 | $-0.15 | $-0.19 | $-0.19 | $-0.18 | $0.00 | $-0.02 | |
| Shares (Basic) | -27,634,739 | 13,886,797 | 13,791,913 | 13,788,414 | -27,228,373 | 13,700,627 | 13,593,766 | 13,593,766 | -27,049,997 | 13,593,758 | 13,497,061 | 13,506,782 | -27,068,159 | 13,558,642 | 13,528,643 | 13,522,433 | |
| Shares (Diluted) | -28,300,663 | 13,886,797 | 14,457,837 | 13,788,414 | -28,157,455 | 14,364,904 | 14,016,953 | 14,042,379 | -27,049,997 | 13,593,758 | 13,497,061 | 13,506,782 | -27,068,159 | 13,558,642 | 13,528,643 | 13,522,433 | |
| EBITDA | · | $65.0K | $542.0K | $-169.0K | · | $5M | $1M | $2M | · | $-2M | $-1M | $-2M | · | $-2M | $567.0K | $215.0K |
Bilanz 22
| Kennzahl | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5M | $7M | $9M | $10M | $10M | $3M | $3M | $3M | $3M | $4M | $6M | $5M | $10M | $12M | $11M | $8M | |
| Receivables | $13M | $12M | $12M | $9M | $11M | $16M | $10M | $9M | $10M | $8M | $8M | $9M | $8M | $8M | $9M | $9M | |
| Prepaid Expense | $1M | $991.0K | $1M | $1M | $1M | $713.0K | $860.0K | $1M | $1M | $835.0K | $780.0K | $1M | $1M | $661.0K | $834.0K | $958.0K | |
| Current Assets | $19M | $20M | $21M | $21M | $22M | $20M | $14M | $13M | $14M | $13M | $14M | $15M | $19M | $20M | $21M | $18M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $8M | $8M | |
| PP&E (Gross) | $16M | $16M | $16M | $16M | $16M | $17M | $16M | $16M | $16M | $16M | $16M | $16M | $16M | $15M | $14M | $14M | |
| Accum. Depreciation | $13M | $12M | $12M | $12M | $12M | $12M | $11M | $11M | $10M | $10M | $9M | $9M | $9M | $7M | $7M | $6M | |
| Goodwill | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | |
| Other Non-current Assets | $212.0K | $196.0K | $196.0K | $196.0K | $196.0K | $185.0K | $185.0K | $185.0K | $185.0K | $185.0K | $185.0K | $184.0K | $15.0K | $15.0K | $15.0K | $15.0K | |
| Total Assets | $27M | $28M | $30M | $31M | $32M | $31M | $25M | $25M | $26M | $27M | $28M | $30M | $34M | $36M | $36M | $34M | |
| Accounts Payable | $7M | $6M | $6M | $5M | $4M | $5M | $5M | $5M | $6M | $5M | $5M | $6M | $5M | $4M | $5M | $3M | |
| Accrued Liabilities | $3M | $3M | $2M | $2M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Current Liabilities | $20M | $21M | $22M | $23M | $24M | $20M | $19M | $19M | $22M | $22M | $21M | $20M | $22M | $21M | $19M | $17M | |
| Capital Leases | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $6M | $6M | $6M | $7M | $7M | $7M | $8M | $8M | $8M | |
| Other Non-current Liabilities | $7.0K | $27.0K | $46.0K | $66.0K | $85.0K | $285.0K | $324.0K | $363.0K | $401.0K | $439.0K | $476.0K | $514.0K | $551.0K | $588.0K | $624.0K | $660.0K | |
| Total Liabilities | $23M | $24M | $26M | $27M | $29M | $25M | $25M | $25M | $28M | $29M | $28M | $28M | $30M | $29M | $27M | $25M | |
| Common Stock | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | |
| Retained Earnings | $-81M | $-80M | $-80M | $-80M | $-80M | $-78M | $-83M | $-83M | $-85M | $-84M | $-82M | $-80M | $-77M | $-75M | $-72M | $-72M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $676.0K | $74.0K | · | · | · | |
| Stockholders' Equity | $4M | $4M | $4M | $4M | $4M | $5M | $681.0K | $-332.0K | $-2M | $-2M | $93.0K | $2M | $5M | $7M | $9M | $9M | |
| Liabilities + Equity | $27M | $28M | $30M | $31M | $32M | $31M | $25M | $25M | $26M | $27M | $28M | $30M | $34M | $36M | $36M | $34M | |
| Shares Outstanding | 13,886,826 | 13,886,826 | 13,886,326 | 13,788,421 | 13,777,170 | 13,705,570 | 13,698,903 | 13,593,766 | 13,593,766 | 13,593,766 | 13,593,766 | 13,484,110 | 13,544,228 | 13,558,650 | 13,558,650 | 13,522,441 |
Cashflow 11
| Kennzahl | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $344.0K | $341.0K | $357.0K | $358.0K | $354.0K | $398.0K | $399.0K | $449.0K | $490.0K | $481.0K | $484.0K | $445.0K | $437.0K | $575.0K | $560.0K | $528.0K | |
| Stock-based Comp | $357.0K | $423.0K | $249.0K | $208.0K | $131.0K | $256.0K | $9.0K | $258.0K | $263.0K | $379.0K | $53.0K | $423.0K | $208.0K | $331.0K | $119.0K | $206.0K | |
| Other Non-cash | · | · | · | $470.0K | · | · | · | $-2M | · | · | · | $-2M | · | · | · | $-581.0K | |
| Operating Cash Flow | $-2M | $-1M | $-2M | $600.0K | $7M | $490.0K | $-283.0K | $311.0K | $-2M | $-919.0K | $589.0K | $-4M | $-692.0K | $2M | $3M | $-195.0K | |
| CapEx | $239.0K | $37.0K | $242.0K | $46.0K | $253.0K | $42.0K | $94.0K | $0 | $-3.0K | $18.0K | $79.0K | $668.0K | $760.0K | $754.0K | $604.0K | $754.0K | |
| Investing Cash Flow | $-238.0K | $-14.0K | $-242.0K | $-46.0K | $-253.0K | $-42.0K | $-94.0K | $0 | $3.0K | $-18.0K | $-79.0K | $-668.0K | $-760.0K | $-754.0K | $-604.0K | $-754.0K | |
| Stock Repurchased | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $32.0K | $602.0K | $74.0K | $0 | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | · | · | $0 | · | · | · | $-602.0K | · | · | · | · | |
| Financing Cash Flow | $-19.0K | $-36.0K | $168.0K | $-14.0K | $-32.0K | $0 | $239.0K | $-37.0K | $-37.0K | $-108.0K | $134.0K | $-590.0K | $-75.0K | $0 | $86.0K | $0 | |
| Net Change in Cash | $-2M | $-1M | $-2M | $540.0K | $7M | $448.0K | $-138.0K | $274.0K | $-2M | $-1M | $644.0K | $-5M | $-2M | $819.0K | $3M | $-949.0K | |
| Free Cash Flow | · | · | · | $554.0K | · | · | · | $311.0K | · | · | · | $-5M | · | · | · | $-949.0K |
Rentabilität 7
| Kennzahl | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -1.7% | 1.2% | -3.8% | · | 26.4% | 5.4% | 9.4% | · | -21.4% | -16.9% | -20.3% | · | -19.2% | 0.05% | -2.1% | |
| Net Margin | · | -1.7% | 1.8% | -3.1% | · | 26.4% | 5.4% | 9.3% | · | -21.1% | -17.9% | -20.4% | · | -19.1% | -0.11% | -2.3% | |
| Pretax Margin | · | -1.4% | 1.7% | -3.2% | · | 26.5% | 5.5% | 9.5% | · | -21.0% | -17.8% | -20.2% | · | -19.0% | -0.01% | -2.2% | |
| EBITDA Margin | · | 0.39% | 3.6% | -1.2% | · | 28.7% | 8.4% | 12.6% | · | -17.4% | -12.7% | -16.8% | · | -14.7% | 4.0% | 1.6% | |
| ROA | · | -0.94% | 0.97% | -1.6% | · | 15.7% | 2.7% | 4.8% | · | -8.0% | -6.4% | -8.0% | · | -7.0% | -0.05% | -1.0% | |
| ROE | · | -5.7% | 11.1% | -27.5% | · | 263.6% | 188.1% | 167.2% | · | -101.1% | -44.7% | -47.1% | · | -29.9% | -0.19% | -3.9% | |
| ROIC | · | -7.6% | 4.1% | -15.5% | · | 81.8% | 105.9% | -394.0% | · | 125.8% | -2113.4% | -135.6% | · | -35.0% | 0.61% | -3.3% |
Liquidität & Solvenz 2
| Kennzahl | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 1.0 | 1.0 | 0.9 | · | 1.0 | 0.7 | 0.7 | · | 0.6 | 0.7 | 0.7 | · | 1.0 | 1.1 | 1.1 | |
| Quick Ratio | · | 0.9 | 0.9 | 0.9 | · | 1.0 | 0.7 | 0.6 | · | 0.6 | 0.6 | 0.7 | · | 0.9 | 1.1 | 1.0 |
Effizienz 2
| Kennzahl | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.6 | 0.5 | 0.5 | · | 0.6 | 0.5 | 0.5 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | |
| Receivables Turnover | · | 1.2 | 1.4 | 1.5 | · | 1.4 | 1.5 | 1.6 | · | 1.5 | 1.4 | 1.4 | · | 1.5 | 1.7 | 1.6 |
Bewertung (TTM) 10
| Kennzahl | Trend | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | $63M | $60M | $59M | · | $57M | $51M | $50M | · | $49M | $51M | $53M | · | $54M | $53M | $50M | |
| Net Income TTM | · | $4M | $5M | $6M | · | $4M | $-3M | $-6M | · | $-10M | $-7M | $-5M | · | $-2M | $729.0K | $573.0K | |
| Market Cap | · | $102M | $95M | $87M | · | $151M | $54M | $65M | · | $79M | $74M | $88M | · | $56M | $94M | $117M | |
| P/E | · | 26.1 | 19.5 | 15.0 | · | 42.3 | -19.6 | -10.9 | · | -8.2 | -10.5 | -16.7 | · | -27.4 | 138.8 | 216.5 | |
| P/S | · | 1.6 | 1.6 | 1.5 | · | 2.7 | 1.0 | 1.3 | · | 1.6 | 1.4 | 1.6 | · | 1.0 | 1.8 | 2.3 | |
| P/B | · | 23.7 | 22.7 | 24.8 | · | 27.5 | 78.7 | -196.1 | · | -38.4 | 798.1 | 46.1 | · | 7.9 | 10.3 | 13.0 | |
| P / Tangible Book | · | 25.7 | 24.7 | 27.5 | · | 29.3 | 154.8 | · | · | · | · | 55.9 | · | 8.3 | 10.6 | 13.5 | |
| P / Cash Flow | · | · | · | 145.2 | · | · | · | 209.4 | · | · | · | -22.0 | · | · | · | -600.5 | |
| P / FCF | · | · | · | 157.3 | · | · | · | 209.4 | · | · | · | -18.8 | · | · | · | -123.4 | |
| Earnings Yield | · | 3.8% | 5.1% | 6.7% | · | 2.4% | -5.1% | -9.2% | · | -12.2% | -9.5% | -6.0% | · | -3.6% | 0.72% | 0.46% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 | |
|---|---|---|---|---|---|
| Umsatz | $59M | $57M | $50M | $54M | $49M |
| Betriebsgewinnmarge % | -1.9% | 8.0% | -14.7% | -9.8% | 1.2% |
| Nettoergebnis | $-1M | $5M | $-7M | $-5M | $548.0K |
| Verwässerte EPS | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 |
Bilanz
| 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 1.0 | 0.9 | 0.6 | 0.9 | 1.1 |
| Quick Ratio | 0.9 | 0.9 | 0.6 | 0.8 | 1.1 |
Cashflow
| 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 | |
|---|---|---|---|---|---|
| Freier Cashflow | $-5M | $7M | $-7M | $1M | $4M |
Handelssignale Aktuelle Kauf-/Verkaufssignale mit Einstiegspreis und Risiko-Ertrags-Verhältnis
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 29 Einreicher · $34.2M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 7 (+3 vs. Vorquartal) | 2 (-3 vs. Vorquartal) | 2 (-3 vs. Vorquartal) | 7 (+1 vs. Vorquartal) | -27K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| BATTERY MANAGEMENT CORP. | $14.917.506 | 2.421.673 | 43,56% | Aktien |
| NEA Management Company, LLC | $10.556.515 | 1.713.720 | 30,82% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.856.334 | 301.353 | 5,42% | Aktien |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | $1.821.253 | 295.658 | 5,32% | Aktien |
| MORGAN STANLEY | $1.450.064 | 235.400 | 4,23% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $856.480 | 139.039 | 2,50% | Aktien |
| Mink Brook Asset Management LLC | $685.842 | 111.338 | 2,00% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $392.213 | 63.653 | 1,15% | Aktien |
| HighTower Advisors, LLC | $258.110 | 41.901 | 0,75% | Aktien |
| VANGUARD GROUP INC | $227.975 | 32.992 | 0,67% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $204.752 | 33.239 | 0,60% | Aktien |
| NORTHERN TRUST CORP | $171.926 | 27.910 | 0,50% | Aktien |
| STATE STREET CORP | $161.410 | 26.203 | 0,47% | Aktien |
| BANK OF AMERICA CORP /DE/ | $134.152 | 21.778 | 0,39% | Aktien |
| Bank of New York Mellon Corp | $130.068 | 21.115 | 0,38% | Aktien |
| CITADEL ADVISORS LLC | $112.697 | 18.295 | 0,33% | Aktien |
| ESSEX INVESTMENT MANAGEMENT CO LLC | $112.241 | 18.221 | 0,33% | Aktien |
| Mesirow Financial Investment Management, Inc. | $97.328 | 15.800 | 0,28% | Aktien |
| MERCER GLOBAL ADVISORS INC /ADV | $78.694 | 12.775 | 0,23% | Aktien |
| Vanguard Global Advisers, LLC | $12.893 | 2.093 | 0,04% | Aktien |
| BlackRock, Inc. | $8.624 | 1.400 | 0,03% | Aktien |
| ACADIAN ASSET MANAGEMENT LLC | $125 | 20.523 | 0,00% | Aktien |
| BARCLAYS PLC | $80 | 13 | 0,00% | Aktien |
| Cambridge Investment Research Advisors, Inc. | $75 | 12.252 | 0,00% | Aktien |
| JPMORGAN CHASE & CO | $71 | 11 | 0,00% | Aktien |
| Cassaday & Co Wealth Management LLC | $62 | 10 | 0,00% | Aktien |
| SBI Securities Co., Ltd. | $25 | 4 | 0,00% | Aktien |
| FMR LLC | $5 | 1 | 0,00% | Aktien |
| Capital Advisors, Ltd. LLC | $0 | 48 | 0,00% | Aktien |
Unternehmensinsider 14 Insider · 5 Führungskräfte · 9 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Joel Ackerman | Chief Executive Officer | 19. November 2015 A | 3.643.000 | 0 | 0 | $0 |
| CHAMPIONS SPORTS INC | Chairman, President and CEO | 11. Oktober 2004 P | 9.548.000 | 0 | 0 | $0 |
| Ronnie Morris | President | 19. November 2015 A | 3.643.000 | 0 | 0 | $0 |
| Douglas D Burkett | President | 3. Oktober 2008 P | — | 0 | 0 | $0 |
| David Barry Miller | Vice President, Finance | 16. März 2015 A | — | 0 | 0 | $0 |
| Scott R. Tobin | Direktor | 12. Oktober 2021 M | 20.000 | 0 | 0 | $0 |
| Daniel Newman Mendelson | Direktor | 1. November 2016 A | 750.000 | 0 | 0 | $0 |
| David Sidransky | Direktor | 1. November 2016 A | 10.675.000 | 0 | 0 | $0 |
| Abba David Poliakoff | Direktor | 2. November 2015 A | 638.667 | 0 | 0 | $0 |
| Arthur G Epker III | Direktor | 13. Oktober 2014 A | — | 0 | 0 | $0 |
| Ana Stancic | Direktor | 14. Juli 2011 A | — | 0 | 0 | $0 |
| Michael M. Brown | 10%-Eigentümer | 28. Januar 2013 A | 16.031.040 | 0 | 0 | $0 |
| James Martell | — | 6. Januar 2012 G | 1.784.828 | 0 | 0 | $0 |
| Durwood Settles | — | 15. Januar 2007 A | — | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 9 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| New Enterprise Associates 14, L.P., NEA Partners 14, L.P., NEA 14 GP, LTD, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Mohamad Makhzoumi, Scott D. Sandell ×2 Einreichungen | 6. Mai 2024 | — | Erste Einreichung | — | SEC |
| Norman H. Pessin, Brian Pessin ×2 Einreichungen | 8. August 2017 | — | Erste Einreichung | Passive Anlage | SEC |
| PAR Investment Partners, L.P., PAR Group, L.P., PAR Capital Management, Inc., Arthur G. Epker, III ×4 Einreichungen | 28. Oktober 2016 | — | Erste Einreichung | — | SEC |
| Joel Ackerman ×2 Einreichungen | 23. März 2015 | — | Erste Einreichung | Passive Anlage | SEC |
| Ronnie Morris ×2 Einreichungen | 23. März 2015 | — | Erste Einreichung | Passive Anlage | SEC |
| Battery Ventures IX, L.P., Battery Investment Partners IX, LLC, Battery Partners IX, LLC, Battery Management Corp., Scott R. Tobin, Thomas J. Crotty, Richard D. Frisbie, Kenneth P Lawler, R. David Tabors, Roger H. Lee, Neeraj Agrawal, Michael M. Brown, Jesse Feldman ×4 Einreichungen | 16. März 2015 | — | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 29. Mai 2007 | — | Erste Einreichung | — | SEC |
| Manuel Hidalgo. | 18. Januar 2007 | — | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 11. Januar 2007 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 5 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| DCOR · Dimensional ETF Trust | 0,00% | 808 NS | 30. April 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,00% | 201 NS | 30. April 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15. Juli 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | — | — | 15. Juli 2026 | Täglich |
| IWC · iShares Trust | — | — | 18. August 2026 | Täglich |